CSL (ASX:CSL) share price higher on COVID-19 vaccine update

The CSL Limited (ASX:CSL) share price is pushing higher on Thursday after releasing an update on its COVID-19 vaccine plans…

| More on:
doctor making thumbs up gesture and holding vial labelled 'covid-19 vaccine' representing covid shares

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price is pushing higher today after the release of an announcement.

At the time of writing the biotherapeutics company's shares are up over 1% to $295.62.

What did CSL announce?

This morning CSL announced that its Seqirus vaccines business has signed a final agreement with the Commonwealth of Australia.

This agreement is for the supply of 51 million doses of the University of Queensland-CSL COVID-19 vaccine candidate (V451), should clinical trials be successful.

According to the release, it also includes an up-front financial commitment from the Government to support the clinical and technical development activities that CSL will need to assume in order to progress V451.

Furthermore, if clinical trials are successful, the agreement secures access to onshore production and supply of the vaccine for Australia.

What is V451?

The company advised that it has been working hard to respond to the current COVID-19 pandemic and has invested significant resources in the rapid development and large-scale manufacture of V451, along with a number of other therapeutic programs.

Pleasingly, the large-scale Phase 2b/3 clinical study for V451 is almost ready. Management notes that it will be a randomised, observer-blinded, placebo-controlled study across numerous countries and upwards of 100 sites.

The study will evaluate efficacy, immunogenicity, and safety in adults aged 18 years and above.

Subject to progress in the current Phase 1 study, the first subject for the Phase 2b/3 would be enrolled in December 2020, with the goal of completing recruitment by March 2021.

Management commented: "We are committed to demonstrating the vaccine is safe and effective prior to availability in the market. Discussions have already commenced with the Australian Therapeutic Goods Administration (TGA) to ensure this goal is met, while also making the vaccine available to the Australian population in the shortest possible time."

In addition, CSL advised that it is working to engage partner organisations to assist with production of further doses with the goal of providing broader access to the vaccine, should clinical trials be successful.

This is on top of the agreement the company has signed with the Government to manufacture the Oxford University/AstraZeneca vaccine candidate (AZD1222) if successful.

Though, given the risk, effort, cost and uncertainty associated with the development of these novel vaccines, management warned that it is too early to calculate the financial impact of these activities.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

asx share price boosted by us investment represented by hand waving US flag across winning athlete
Best Shares

Here are the best-performing ASX 200 shares since the US election result

We reveal the 10 ASX stocks that have had the highest share price gains since the US Presidential election.

Read more »

a man sits back from his laptop computer with both hands behind his head feeling happy to see the Brambles share price moving significantly higher today
Industrials Shares

Up 39% in a year, is there more growth to come for this ASX 200 share?

IML Equity Analyst Josh Freiman shares his views on a major ASX 200 industrial stock.

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Catapult, Flight Centre, Nufarm, and Xero shares are storming higher today

These shares are having a strong session on Thursday. But why? Let's find out.

Read more »

drug capsule opening up to reveal dollar signs signifying rising asx share price
Healthcare Shares

3 ASX healthcare shares going gangbusters on Thursday

Investors are sending these ASX healthcare stocks soaring today. But why?

Read more »

A young man talks tech on his phone while looking at a laptop. A financial graph is superimposed across the image.
Share Gainers

Here are the top 10 ASX 200 shares today

The ASX 200 made it three-for-three losses in a row this Wednesday.

Read more »

A young woman wearing overalls and a yellow t-shirt kicks one leg in the air showing excitement over the latest ASX 200 shares to hit 52-week highs
Share Gainers

Why Brickworks, James Hardie, Megaport, and OFX shares are charging higher today

These shares are having a good time on hump day. But why?

Read more »

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

ASX investors endured another day of selling this Tuesday.

Read more »

Man pointing at a blue rising share price graph.
Technology Shares

Guess which ASX 300 tech stock is already up 64% in November!

The ASX 300 tech stock is surging higher this month. But why?

Read more »